Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37Liver Neoplasms 20Neoplasms 17Leukemia, Myeloid, Acute 13Neoplasm Metastasis 11Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Pancreatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Breast Neoplasms 6Brain Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 5Prostatic Neoplasms 5Multiple Myeloma 5Lung Neoplasms 5Kidney Neoplasms 5Recurrence 4Glioblastoma 4Colorectal Neoplasms 4Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Leukemia, Promyelocytic, Acute 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3

Interventions

pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2satraplatin 1ixazomib 1X-Rays 1Valproic Acid 1Trastuzumab 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1Capecitabine 1Albumin-Bound Paclitaxel 1AH 111585 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancers × Sorafenib × Clear all
NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡